Genentech's Avastin Labeling Adds Warning On Thromboembolic Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Updated labeling includes warning on arterial thromboembolic events described in August "Dear Healthcare Provider" letter. Patients treated with Avastin plus chemotherapy had a 4.4% incidence of thromboembolic events versus 1.9% in patients on chemotherapy alone.